King Luther Capital Management Corp Acquires New Position in Haleon plc (NYSE:HLN)

King Luther Capital Management Corp bought a new position in Haleon plc (NYSE:HLN) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,915 shares of the company’s stock, valued at approximately $158,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sculptor Capital LP increased its position in shares of Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after acquiring an additional 3,592,000 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Haleon by 8.6% during the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Haleon by 95.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after purchasing an additional 954,622 shares during the last quarter. Natixis Advisors LLC increased its holdings in shares of Haleon by 142.5% in the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares in the last quarter. Finally, Raymond James & Associates raised its stake in shares of Haleon by 14.7% in the second quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock worth $33,205,000 after purchasing an additional 515,651 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating on the stock. Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Stock Up 1.0 %

Haleon stock opened at $9.65 on Monday. The stock has a market cap of $43.68 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 2.88 and a beta of 0.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a fifty day moving average of $10.01 and a 200 day moving average of $9.39. Haleon plc has a one year low of $7.89 and a one year high of $10.80.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.